

AMENDMENTS TO THE CLAIMS

1. (Currently Amended): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B ~~SEQ ID NO: 243~~, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

2. (Original): The compound of claim 1 which is an antisense oligonucleotide.

3. (Cancelled).

4. (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. (Original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (Original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. (Original): The composition of claim 11 further comprising a colloidal dispersion system.

13. (Original): The composition of claim 11 wherein the compound is an antisense oligonucleotide.

14. (Currently Amended): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of ~~an active site on a~~ the nucleic acid molecule encoding PTP1B sequence SEQ ID NO: 243, wherein said hybridization at said 8-nucleobase portion modulates expression of PTP1B.

15. (Original): A method of inhibiting the expression of PTP1B in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of PTP1B is inhibited.

16. (Original): The method of claim 15 wherein the cells or tissues are human cells or tissues.

17. (Original): The method of claim 15 wherein the cells or tissues are rodent cells or tissues.

18. (Original): The method of claim 17 wherein the rodent cells or tissues are mouse cells or tissues.

19. (Original): The method of claim 17 wherein the rodent cells or tissues are rat cells or tissues.

20. (Original): The method of claim 15 wherein the cells or tissues are liver, kidney or adipose cells or tissues.

21. (Cancelled)

22. (Currently Amended): The method of claim 24 30 wherein the animal is a human.

Claims 23 and 24 (Cancelled)

25. (Currently Amended): The method of claim 24 32, wherein ~~the disease or condition is~~ said animal has Type 2 diabetes.

26. (Currently Amended): The method of claim 24 29 wherein ~~the disease or condition is~~ obesity said animal is obese.

Claims 27 and 28. (Cancelled)

29. (Original): A method of decreasing blood glucose levels in an animal comprising administering to said animal the compound of claim 1.

30. (Original): The method of claim 29 wherein the animal is a human or a rodent.

31. (Original): The method of claim 29 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

32. (Original): The method of claim 29 wherein the animal is a diabetic animal.

Claims 33 - 36. (Cancelled)

37. (Currently Amended): The method of claim 33 44 wherein the ~~disease or condition is~~ animal has Type 2 diabetes.

38. (Currently Amended): The method of claim 33 41 wherein ~~the disease or condition is~~ obesity said animal is obese.

Claims 39 - 40. (Cancelled)

41. (Original): A method of preventing or delaying the onset of an increase in blood glucose levels in an animal comprising administering to said animal the compound of claim 1.

42. (Original): The method of claim 41 wherein the animal is a human or a rodent.

43. (Original): The method of claim 41 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

44. (Original): The method of claim 41 wherein the animal is a diabetic animal.

45. (New): A method of lowering plasma insulin levels in an animal comprising administering to said animal the compound of claim 1.

46. (New): The method of claim 45 wherein said animal is a non- human primate or human.

47. (New): A method of increasing insulin sensitivity in an animal comprising administering to said animal the compound of claim 1.

48. (New): The method of claim 15, wherein said cells or tissues are monkey cells or tissues.

49. (New): A method of treating, or delaying the onset of, Type 2 diabetes in an animal comprising administering to said animal the compound of claim 1.